换一批
换一批Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
第一作者：
Christina L,Addison
第一单位：
Program for Cancer Therapeutics, Ottawa Hospital Research Institute, Box 926, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6 ; Department of Medicine, University of Ottawa, Ottawa, ON, Canada ; Department of Biochemistry, Microbiology and Immunology University of Ottawa, Ottawa, ON, Canada.
作者：
关键词
BP, bisphosphonateBPI, brief pain inventoryBiomarkerBone metastasisBreast cancerCTx, C-telopeptideER, estrogen receptorFACT-BP, Functional assessment of cancer therapy-bone painOS, overall survivalPFS, progression free survivalPR, progesterone receptorPatient outcomeRANKL, Receptor Activator NF-KB ligandSRE, skeletal related eventSkeletal related eventTGF-β, transforming growth factor betaVEGF, vascular endothelial growth factorVandetanibsVEGFR, soluble vascular endothelial growth factor receptoruNTx, urinary N-telopeptide
DOI
10.1016/j.jbo.2015.04.001
PMID
26579488
发布时间
2020-09-30
- 浏览72
Journal of bone oncology
2015年4卷2期
47-53页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
